Infliximab treatment in pathology-confirmed neurosarcoidosis

OBJECTIVE: To assess the efficacy and risks of treatment with infliximab (anti–tumor necrosis factor alpha) in pathology-confirmed neurosarcoidosis. METHODS: In a retrospective study in 2 tertiary referral centers in the Netherlands, we analyzed clinical characteristics, complications, and outcome o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neurol Neuroimmunol Neuroinflamm
Glavni autori: Fritz, Daan, Timmermans, Wilhelmina M.C., van Laar, Jan A.M., van Hagen, P. Martin, Siepman, Theodora A.M., van de Beek, Diederik, Brouwer, Matthijs C.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7413716/
https://ncbi.nlm.nih.gov/pubmed/32718952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000847
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items